{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:06:54Z","timestamp":1791389214153,"version":"4.3.3"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.diabres.2022.110191","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T13:48:44Z","timestamp":1669470524000},"page":"110191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study"],"prefix":"10.1016","volume":"194","author":[{"given":"Jiyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-3553","authenticated-orcid":false,"given":"Bong-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Do","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Yoon Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Hee Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-1738","authenticated-orcid":false,"given":"You-Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Man","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Hyeon Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2022.110191_b0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2022.110191_b0010","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2022.110191_b0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.diabres.2022.110191_b0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2022.110191_b0025","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.diabres.2022.110191_b0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2022.110191_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2022.110191_b0040","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.diabres.2022.110191_b0045","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.21827","article-title":"Incidence and natural course of fatty liver in the general population: the Dionysos study","volume":"46","author":"Bedogni","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2022.110191_b0050","article-title":"Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up","volume":"8","author":"Wu","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.diabres.2022.110191_b0055","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","article-title":"The metabolic syndrome as a predictor of nonalcoholic fatty liver disease","volume":"143","author":"Hamaguchi","year":"2005","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.diabres.2022.110191_b0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2022.110191_b0065","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2337\/dc15-0140","article-title":"Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes","volume":"38","author":"Yamazaki","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.110191_b0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2018.03.018","article-title":"Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins","volume":"272","author":"Sung","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2022.110191_b0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.diabres.2022.110191_b0080","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.diabres.2022.110191_b0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01374-8","article-title":"The association of hepatic steatosis and fibrosis with heart failure and mortality","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2022.110191_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01483-y","article-title":"The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study","volume":"21","author":"Park","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.diabres.2022.110191_b0095","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4093\/dmj.2014.38.5.395","article-title":"Background and data configuration process of a nationwide population-based study using the korean national health insurance system","volume":"38","author":"Song","year":"2014","journal-title":"Diabetes Metab J"},{"issue":"11","key":"10.1016\/j.diabres.2022.110191_b0100","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41366-021-00922-2","article-title":"Early mortality and cardiovascular disease, varied association with body mass index and its changes in insulin-treated diabetes: a nationwide study","volume":"45","author":"Lee","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.diabres.2022.110191_b0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/alcalc\/37.5.409","article-title":"Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms","volume":"37","author":"Agarwal","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.diabres.2022.110191_b0110","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/s41598-017-07549-2","article-title":"Association between alcohol consumption pattern and the incidence risk of type 2 diabetes in Korean men: A 12-years follow-up study","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"48","key":"10.1016\/j.diabres.2022.110191_b0115","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/eurheartj\/ehx585","article-title":"Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study","volume":"38","author":"Kim","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2022.110191_b0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2022.110191_b0125","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","article-title":"Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"90","author":"Spengler","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.diabres.2022.110191_b0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3748\/wjg.v19.i1.57","article-title":"Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification","volume":"19","author":"Zelber-Sagi","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.diabres.2022.110191_b0135","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.diabres.2022.110191_b0140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2022.110191_b0145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4093\/dmj.2020.0010","article-title":"Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: a position statement of the fatty liver research group of the korean diabetes association","volume":"44","author":"Lee","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2022.110191_b0150","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fmed.2019.00202","article-title":"Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review","volume":"6","author":"Ismaiel","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.diabres.2022.110191_b0155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: a Call to Action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2022.110191_b0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.diabres.2022.110191_b0165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.diabres.2022.110191_b0170","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.110191_b0175","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2022.110191_b0180","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: a Meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.diabres.2022.110191_b0185","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.diabres.2022.110191_b0190","first-page":"4697","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: a Randomized, Double-Blind","volume":"37","author":"Taheri","year":"2020","journal-title":"Placebo-Controlled Trial Adv Ther"}],"updated-by":[{"DOI":"10.1016\/j.diabres.2024.111742","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722010051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722010051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:57Z","timestamp":1759173837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722010051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":38,"alternative-id":["S0168822722010051"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110191","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.diabres.2024.111742","asserted-by":"object"}]},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110191"}}